
Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual ... Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.06 | -1.61290322581 | 3.72 | 4.462 | 3.5419 | 38847 | 3.93549183 | CS |
4 | 0.85 | 30.2491103203 | 2.81 | 5.2683 | 2.65 | 206828 | 3.75693469 | CS |
12 | 1.22 | 50 | 2.44 | 5.2683 | 2.3186 | 68776 | 3.69522385 | CS |
26 | -0.66 | -15.2777777778 | 4.32 | 5.2683 | 2.2 | 36236 | 3.66163834 | CS |
52 | -0.5 | -12.0192307692 | 4.16 | 5.2683 | 2.2 | 27671 | 3.77530701 | CS |
156 | -5.34 | -59.3333333333 | 9 | 10 | 2.2 | 29243 | 4.54854655 | CS |
260 | -6.34 | -63.4 | 10 | 56.8 | 2.2 | 654494 | 27.90260686 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.